Cystatin C is a Better Marker of Renal Dysfunction in Hypertensive Pregnancies

1Anjana Singh, 2Mamta Gupta, 3Rajeev Ranjan, 4Vandana Saini, 5SK Gupta

ABSTRACT

Background: Glomerular endotheliosis is an essential component in the pathophysiology of gestational hypertension (GH) and preeclampsia (PE) which results in renal dysfunction. This is not always detected by routine renal function tests, such as serum creatinine, urea, and uric acid. Cystatin C, an endogenous cysteine protease inhibitor, is completely absorbed by renal tubules and has been shown to be an ideal marker of glomerular filtration rate (GFR), which needs to be evaluated in assessing renal dysfunction occurring in GH and PE.

Aims: The present study is designed to evaluate serum cystatin C levels in normal pregnancy, GH, and PE and compare its efficacy with traditional renal function tests.

Materials and methods: In this prospective cross-sectional study, 75 subjects enrolled, comprised of 25 subjects each of normal pregnancy, GH, and PE. Serum cystatin C, blood urea, serum creatinine, serum uric acid, and urinary protein/creatinine ratio were estimated in all subjects prior to delivery.

Results: All renal parameters including cystatin C were significantly raised in GH and PE compared with control group. However, only serum cystatin C level (and no other renal parameters) was significantly higher in PE group compared with GH group. Area under the curve for cystatin C was maximum (0.917) compared with other parameters. Cystatin C had a higher sensitivity and specificity than other conventional markers.

Conclusion: Serum cystatin C is a better marker of renal dysfunction in hypertensive pregnancies.

Keywords: Cystatin C, Gestational hypertension, Hypertensive pregnancies, Preeclampsia, Renal dysfunction.


Source of support: The study was done by institutional funding.

Conflict of interest: None.

INTRODUCTION

Gestational hypertension (GH) and preeclampsia (PE) are pregnancy-specific hypertensive disorders. Both carry high maternal and fetal risk. Termination of pregnancy is the only definitive cure for these conditions.

In normal pregnancy, glomerular filtration rate (GFR) is physiologically increased by 50%.1 But glomerular endotheliosis, seen in both GH and PE, leads to decrease in GFR than in normal pregnancy.2 This decreased GFR, can eventually lead to renal failure in PE. Kidney function therefore needs to be closely monitored in women with GH and PE so that timely termination of pregnancy for a better fetomaternal outcome can be done.

The traditional markers of renal function followed widely, i.e., serum creatinine, urea, and uric acid levels, have several limitations.

Serum creatinine, though most widely used, is significantly influenced by body weight, physical activity, and diet.3 After filtration by the glomerulus, it is reabsorbed and then secreted by tubules. The secretion increases with the increase in serum creatinine. Initially thus, serum creatinine does not rise and remains normal till about 50% of renal function is lost. Thus, there is a creatinine blind area where mild-to-moderate decrease in GFR is not reflected in serum creatinine levels.

Uric acid is also filtered, reabsorbed, and secreted by the kidney. Its levels are also influenced by diet and alcohol consumption. Increased tissue breakdown, hypovolemia, and acidosis seen in hypertensive pregnancies also increase uric acid level. Thus, increased uric acid levels may not necessarily indicate renal dysfunction.

Blood urea, the major nitrogen-containing catabolic product of proteins in humans, is widely regarded as a test of renal function but is affected by protein intake, liver metabolic capacity, renal perfusion, and hydration.

Serum cystatin C is a new emerging endogenous marker of renal function. It is produced by all nucleated cells and is a cysteine protease inhibitor. Its blood levels are not dependent on age, sex, diet, muscle mass, or inflammatory process. Unlike creatinine, it is almost exclusively eliminated from the circulation by glomerulus. Its serum concentration reflects GFR more closely than creatinine. Unlike serum creatinine, there is no cystatin C blind area because it is not secreted by tubules. It is
completely reabsorbed and metabolized by tubular cells. Studies have shown superior diagnostic sensitivity of serum cystatin C levels for the detection of mildly impaired GFR.4,5

Serum cystatin C has been studied as a useful marker for assessment of renal dysfunction, in acute kidney injury,6 chronic kidney disease,7 renal transplantation,8 diabetes,9 prediabetes,10 etc., and has been considered better than other traditional markers of renal dysfunction.

Not much work has been done on serum cystatin C as a marker of renal dysfunction in hypertensive disorders of pregnancy, hence, the need for its evaluation.

AIMS AND OBJECTIVES
To evaluate serum cystatin C levels as a marker of renal dysfunction in women with normal pregnancy, GH, and PE and compare it with serum creatinine, blood urea, and serum uric acid.

MATERIALS AND METHODS
This cross-sectional observational study was carried out on in a tertiary care urban hospital, from May 2012 to April 2014. Ethical clearance was obtained from the institutional ethical committee. Written consent was taken from all the women enrolled for the study. The study subjects comprised of three groups of 25 each – group A with normal pregnancy, group B with GH, and group C with PE.

Gestational hypertension was defined as blood pressure (BP) more than 140/90 mm Hg occurring after 20 weeks of pregnancy on two occasions 6 hours apart without significant proteinuria. Preeclampsia was defined as BP more than 140/90 mm Hg occurring after 20 weeks on two occasions 6 hours apart with significant proteinuria, detected by spot urine protein/creatinine ratio more than 0.3,11

Patients with preexisting hypertension, chronic hypertension with superimposed PE, diabetes, renal disease, multiple pregnancy, thyroid disease, and eclampsia were excluded from the study.

Fasting venous blood sample was drawn and serum was separated for estimation of cystatin C and other renal parameters. Spot urine sample was also collected for urinary estimation of protein/creatinine ratio. All samples for analysis were taken at term, on admission to labor ward, or just prior to induction of labor.

Serum cystatin C and urinary albumin (for urinary protein/creatinine ratio) were estimated by immunoturbidimetric assay using Agape's and Erba transasia kits respectively. Serum creatinine, urea, and uric acid and urine creatinine (for urinary protein/creatinine ratio) were assayed by standard enzymatic methods. All assays were carried out on fully automatic Erba XL 300 autoanalyzer.

All the patients were followed till delivery and the relevant details like demographic features and results of renal function tests were recorded in a predesigned proforma. The results were statistically analyzed.

RESULTS
The general demographic profile is shown in Table 1. Except for parity, all the demographic parameters were comparable in the three groups.

Analysis of renal functions revealed that all renal parameters were raised in group C (Table 2); however, only serum cystatin C levels were significantly raised in group C than in group B, not seen with other parameters.

Since serum cystatin C was found to discriminate between groups B and C, its correlation with other renal parameters was studied in all hypertensive pregnant women (n = 50, groups B + C). Cystatin C showed a positive correlation with all the other renal parameters. Urinary proteins had the best correlation with cystatin C followed by urinary protein:creatinine ratio (Table 3).

Receiver operating characteristic (ROC) analysis and area under the curve (AUC) showed that cystatin C had

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal pregnancy</th>
<th>GH</th>
<th>PE</th>
<th>Statistical significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>group A n=25</td>
<td>group B n=25</td>
<td>group C n=25</td>
<td>p-value</td>
</tr>
<tr>
<td>Age (mean±SD)</td>
<td>25.6±2.81 years</td>
<td>25.12±2.55 years</td>
<td>25.2±3.2 years</td>
<td>0.81</td>
</tr>
<tr>
<td>Parity – primi</td>
<td>24%</td>
<td>44%</td>
<td>64%</td>
<td>0.01 S</td>
</tr>
<tr>
<td>P1</td>
<td>52%</td>
<td>32%</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>16%</td>
<td>25%</td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>P3 and more</td>
<td>8%</td>
<td>4%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>POG (mean±SD) days</td>
<td>271.4±7.62</td>
<td>266.84±11.39</td>
<td>260.36±33.87</td>
<td>0.099</td>
</tr>
<tr>
<td>History of high BP in prev. pregnancy</td>
<td>16%</td>
<td>16%</td>
<td>24%</td>
<td>0.704 NS</td>
</tr>
<tr>
<td>Family history of hypertension</td>
<td>12%</td>
<td>12%</td>
<td>16%</td>
<td>0.704 NS</td>
</tr>
</tbody>
</table>

S: Significant; NS: Not significant
Cystatin C is a Better Marker of Renal Dysfunction in Hypertensive Pregnancies

Table 2: Renal parameters in the three groups

<table>
<thead>
<tr>
<th>Renal parameter</th>
<th>Normal preg. group A</th>
<th>GH group B</th>
<th>PE group C</th>
<th>A/B group</th>
<th>A/C group</th>
<th>B/C group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uric acid (mg/dL)</td>
<td>3.86±1.25</td>
<td>5.15±1.05</td>
<td>5.6±1.38</td>
<td>0.001</td>
<td>0.000</td>
<td>0.418</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.728±0.084</td>
<td>0.828±0.067</td>
<td>0.86±0.173</td>
<td>0.010</td>
<td>0.001</td>
<td>0.605</td>
</tr>
<tr>
<td>Urea (mg/dL)</td>
<td>19.48±3.12</td>
<td>23.52±3.4</td>
<td>25.64±7.46</td>
<td>0.017</td>
<td>0.000</td>
<td>0.309</td>
</tr>
<tr>
<td>Cystatin C (mg/L)</td>
<td>0.962±0.232</td>
<td>1.26±0.28</td>
<td>1.62±0.328</td>
<td>0.001</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>

*p value determined by one-way ANOVA followed by Tukey honest significant difference test; <0.05 significant

Table 3: Correlation of serum cystatin C and other renal parameters in hypertensive pregnant women (n=50)

<table>
<thead>
<tr>
<th>With cystatin C</th>
<th>Uric acid</th>
<th>Creatinine</th>
<th>Urinary protein</th>
<th>Urine protein/creatinine ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correlation r-value</td>
<td>0.291</td>
<td>0.325</td>
<td>0.287</td>
<td>0.657</td>
</tr>
<tr>
<td>p-value</td>
<td>0.040</td>
<td>0.021</td>
<td>0.043</td>
<td>0.000</td>
</tr>
</tbody>
</table>

<0.05 significant

Table 4: Analysis and area under the curve for cystatin C and other renal parameters

<table>
<thead>
<tr>
<th>Test result variable(s)</th>
<th>AUC</th>
<th>Std. error</th>
<th>Asymptotic sig.</th>
<th>Lower bound</th>
<th>Upper bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea</td>
<td>0.831</td>
<td>0.053</td>
<td>0.000</td>
<td>0.727</td>
<td>0.936</td>
</tr>
<tr>
<td>Uric acid</td>
<td>0.808</td>
<td>0.056</td>
<td>0.000</td>
<td>0.698</td>
<td>0.919</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>0.796</td>
<td>0.055</td>
<td>0.000</td>
<td>0.688</td>
<td>0.903</td>
</tr>
<tr>
<td>Serum cystatin C</td>
<td>0.917</td>
<td>0.041</td>
<td>0.000</td>
<td>0.837</td>
<td>0.997</td>
</tr>
</tbody>
</table>

<0.05 significant

Table 5: Sensitivity and specificity of cystatin C and other renal parameters

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cut-off value</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea (mg/dL)</td>
<td>21</td>
<td>78%</td>
<td>76%</td>
</tr>
<tr>
<td>Uric acid (mg/dL)</td>
<td>4.1</td>
<td>88%</td>
<td>68%</td>
</tr>
<tr>
<td>S. Creatinine (mg/dL)</td>
<td>0.75</td>
<td>86%</td>
<td>64%</td>
</tr>
<tr>
<td>S. Cystatin C (mg/L)</td>
<td>1.055</td>
<td>94%</td>
<td>88%</td>
</tr>
</tbody>
</table>

<0.05 significant

Table 6: Mode of delivery in different groups

<table>
<thead>
<tr>
<th>Mode of delivery</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Spontaneous, vaginal delivery</td>
<td>19</td>
<td>11</td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td>2 Induction of labor, vaginal delivery</td>
<td>5</td>
<td>11</td>
<td>2</td>
<td>18</td>
</tr>
<tr>
<td>3 LSCS for nonhypertension indication**</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>4 LSCS for hypertension-related indication*</td>
<td>0</td>
<td>4</td>
<td>8</td>
<td>12</td>
</tr>
</tbody>
</table>

In group A, * patients had induction for postmaturity; **Includes patients who had lower segment cesarean section (LSCS) for nonhypertension indication, i.e., transverse lie, breech presentation, placenta previa, cephalopelvic disproportion, etc; * Includes patients who had LSCS for hypertension-related indication, i.e., failed induction for hypertension, uncontrolled BP on multiple antihypertensive drugs, impending eclampsia with poor Bishop score, abruptio placentae, fetal distress with IUGR

Graph 1: Receiver operating characteristic curve for cystatin C and other renal parameters

Graph 2: Mode of delivery in the three groups. IOL: Induction of labor; LSCS: Lower segment cesarean section; HTN: Hypertension
PPH was statistically significant (p-value 0.022, t-test) mean cystatin C in PPH and non-PPH groups was statistically highly significant (p-value 0.008, t-test) (Table 7).

Fetal outcome was evaluated in terms of fetal growth (Tables 8 and 9), fetal weight, and Apgar score (Table 10). In the control group A, only three babies had intrauterine growth restriction (IUGR); none had intrauterine fetal death (IUD). The renal parameters in women with normal growth and IUGR were comparable (Table 8). However, in the hypertensive group, mean creatinine and cystatin C were significantly different in women having normal fetal growth, IUGR, and IUD (Table 9).

The pattern of increase/decrease in various renal parameters was analyzed in hypertensive women having normal growth, IUGR, and IUD (Graphs 3 to 6). It was observed that mean urea levels increased in women having normal fetal growth and IUGR but remained stationary or minimally decreased when IUD occurred (Graph 3). Some increase in mean uric acid occurred in women with normal growth and when IUGR occurred;
Cystatin C is a Better Marker of Renal Dysfunction in Hypertensive Pregnancies

the rise of uric acid was substantial in women who had IUD compared with IUGR (Graph 4). Regarding serum creatinine, it was observed that as IUGR developed from normal growth, creatinine increased substantially but again decreased when IUD occurred from IUGR (Graph 5). Cystatin C, however, increased in a linear pattern in all stages of fetal growth (Graph 6); rising levels therefore reflect directly fetal outcome in terms of fetal growth.

A negative correlation between uric acid, creatinine, and cystatin C with Apgar score at 1 minute in hypertensive pregnant women was seen, but cystatin C had the maximum negative correlation with 1 minute Apgar score. In regard to birth weight, a stronger negative correlation with serum creatinine was observed than with cystatin C (Table 11).

DISCUSSION

Altered renal function is an essential part of pathophysiology of hypertensive disorders of pregnancy due to the characteristic lesion “glomerular endotheliosis” and hemodynamic changes causing decreased GFR, renal dysfunction, and even renal failure. Hence, close monitoring is essential to ascertain the optimal time for delivery in fetomaternal interest.

In search of an ideal renal marker in PE, which may overcome the limitations of the conventional markers, the present study on cystatin C as a marker of renal function was undertaken.

The general demographic profile of study subjects is shown in Table 1. Appropriate statistical tests were applied to all the demographic parameters. Mean age was comparable in all the three groups [p-value 0.81, analysis of variance (ANOVA) test]. Most patients in PE and GH group were primiparas, which was significant (group A vs C p-value 0.01, Fisher exact chi-square test). Mean period of gestation (POG) was less in GH (271.44 days) and PE (260.36 days) groups than in the control group (271.44 days), though not statistically significant (p > 0.05, ANOVA test). History of hypertension in previous pregnancies and family history (sisters, parents/grandparents of women) of hypertension were more common in PE group than in GH or normal pregnancy, though not statistically significant (p-value 1, ANOVA test). These findings confirm the association of known risk factors for the disease, i.e., primiparity, past history of hypertension, and family history.

It was observed in our study that serum levels of all the renal markers cystatin C, creatinine, urea, and uric acid were significantly raised in GH and PE groups compared with the control group (p < 0.01, ANOVA and Tukey test) (Table 2). The raised levels of renal parameters were significant in PE group and GH group compared with control group, signifying some degree of renal dysfunction associated with GH and PE women.

Further, it was observed in our study that only serum cystatin C levels were significantly higher in PE group compared with GH group (p-value 0.00), indicating that it may be an early marker of PE as it is found to be raised significantly even at a nonproteinuric stage of the disease (GH). This finding of our study is significant and is clinically useful in closely monitoring those GH women who have higher cystatin C levels and are likely to develop PE. Hence, cystatin C can be helpful in prognostication of hypertensive pregnant women as GH has a relatively benign course than PE.

Several studies have reported higher cystatin C levels in PE patients than normal pregnant women. It has been reported as a marker of GFR in hypertensive pregnancies, glomeruloendotheliosis, and an early marker of PE. A large number of studies have unequivocally shown serum cystatin C levels a better marker of GFR in nonpregnant healthy women as well as normal pregnant women and also in PE women12-15 than serum creatinine levels.

Cystatin C levels have been estimated in PE subjects in many studies and have been found to be superior.4,12,13,16 A meta-analysis by Dharnidharka et al17 in 46 subjects has found serum cystatin C to be clearly superior to serum creatinine as a marker of GFR measured by correlation.
or mean ROC–AUC plot. We have come across only one study by Padma et al18 who have estimated cystatin C in women with GH as well as PE in which higher cystatin C levels in GH and PE than in normal pregnant controls has been reported. However, in this study,18 serum creatinine has been reported to be a better indicator of renal function. One possible reason could be that they have used Jaffe’s reagent-based kinetic assay than the enzymatic methods used in our study, which has been shown to be more accurate with reference method.19

In our study, we had estimated urinary protein/creatinine ratio to select the patients for groups B or C (cut-off level being 0.3) and it was not the primary aim to correlate cystatin C levels with either urinary protein or urinary protein/creatinine ratio. However, we did find a strong positive correlation of cystatin C with urinary protein and urinary protein/creatinine ratio (r-value 0.657 and 0.630) respectively, with p-value 0.00 (Table 3). Proteinuria itself is the most important marker of glomerular function, supporting our view regarding cystatin C as a marker of renal function in PE and GH where glomeruloendotheliosis is considered to be an essential pathophysiology. This secondary outcome of our study further strengthens the emerging view that increased and rising serum cystatin C levels in women with GH may be an indicator of impending PE, even when there is no proteinuria or at a nonproteinuric stage of the disease. Extrapolated, this observation might be helpful in predicting the development of PE in women with GH and also superimposed PE in a patient having chronic hypertension. Taken together, these are novel findings of our study.

Receiver operating characteristic analysis of the various renal markers in our study revealed maximum AUC for cystatin C (0.917) followed by urea (0.831), uric acid (0.808), and creatinine (0.796), suggesting maximum diagnostic performance of cystatin C to detect renal dysfunction in hypertensive pregnant women (Table 4 and Graph 1). The sensitivity (94%) and specificity (88%) of cystatin C were maximum. Thus, cystatin C appears to pick up more women with renal dysfunction in PE and GH, also at an earlier nonproteinuric stage as indicated in Table 2. Elegwany et al20 have shown a sensitivity of 72.5% and specificity of 100% for cystatin C (Table 5).

In our study, it was observed that cystatin C had a good correlation with fetomaternal outcome. Apgar score at 1 minute had a good correlation with cystatin C (r-value –0.421), though birth weight correlated better with serum creatinine. We had an important and unique observation in our study regarding fetal growth, which we have not come across in any study in the literature with our best efforts. A linear association with cystatin C (Graph 6) and rising cystatin C levels were observed, reflecting deteriorating fetal growth from normal growth to IUGR and IUD. This is in contrast to other renal parameters where fetal deterioration due to hypertensive placental pathology is not reflected always by rising renal parameters (Graphs 3 to 5).

Maternal outcome in terms of PPH also had a good correlation with cystatin C. We have not come across any other study to the best of our efforts where fetomaternal outcome has been correlated with serum cystatin C levels in pregnant hypertensive women.

CONCLUSION

Our study shows serum cystatin C to be a better marker compared with the conventional tests, in detecting renal dysfunction in women with GH and PE. It is clinically useful in closely monitoring those GH women who have higher cystatin C levels and are likely to develop PE. Thus, it can be used for prognostication of hypertensive pregnancies. Its strong positive correlation with urinary protein and protein/creatinine ratio might be helpful in predicting development of PE in women with GH and also superimposed PE in a patient having chronic hypertension. It has been found to correlate well with fetomaternal outcomes in hypertensive disorders of pregnancy.

It was demonstrated that serum cystatin C had a better sensitivity and specificity than the traditional markers of renal dysfunction. Estimation of cystatin C should therefore be included in routine work-up of PE and GH patients.

REFERENCES